Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on ...
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% ...
Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...
The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...
Investing.com - Moderna (NASDAQ: MRNA) reported third quarter EPS of $-0.51, $1.54 better than the analyst estimate of $-2.05. Revenue for the quarter came in at $1.02B versus the consensus estimate ...
MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment ...
Qualcomm (NASDAQ:QCOM) stock dropped 1.4% as fears the chip designer will lose business from Samsung, a key customer, ...
Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...
Mixed earnings results were being mentioned on Thursday as possible catalysts behind Thursday's stock-market action. Shares of Moderna Inc. were up more than 3% after the vaccine maker reported a ...
Investor's Business Daily on MSN
Moderna Cuts Costs As Covid Vaccine Sales Decline; Shares Rise
Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to ...
MRNA) on Thursday reported a loss of $200 million in its third quarter. On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 51 cents. The results exceeded Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback